Who Paid My Doc
Louis Katz
Infectious Disease Davenport, IA Medical Doctor
NPI 1083608772 CMS profile 321598
1351 W Central Park Ave, Davenport, IA 52804
General payments
$11,772
Research payments
$2,380
Ownership & investment interest
$0
Research they led as principal investigator
$767,358
Through program year 2024, Louis Katz of Davenport, IA is reported in the CMS Open Payments database as having received $11,772 across 16 general payments and $2,380 in research payments paid to them. Separately, studies naming them as principal investigator received $767,358 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $52 | 1 | |
| 2023 | General | $15 | 1 | |
| 2021 | General | $2,615 | 3 | |
| 2020 | General | $6,038 | 3 | |
| 2020 | Research | $2,380 | 3 | |
| 2019 | General | $3,052 | 8 |
Beside peers
- Louis Katz
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Louis Katz were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Louis Katz | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,052 | $190 | $60–$862 | $163 |
| 2020 | $6,038 | $124 | $32–$606 | $114 |
| 2021 | $2,615 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $15 | $171 | $57–$787 | $160 |
| 2024 | $52 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
54
Drug cost
$74,481
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 35 | $73,303 | |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | Brand | 19 | $1,178 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Iowa
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Iowa
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.